02:16 PM EDT, 03/13/2026 (MT Newswires) -- Novartis ( NVS ) said Friday the US Food and Drug Administration has approved Cosentyx for pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa.

The drug is already used for adults with hidradenitis suppurativa, a chronic inflammatory skin disease that causes boil-like lesions.

Price: 154.39, Change: +0.14, Percent Change: +0.09